RxDoctor Payments Data

Jung Lee, MD

Ophthalmology · Westwood, NJNPI 1093733156

Payments from drug & device makers

$3,789in general payments, 2019–2025

Across 133 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$758
  • AbbVie$612
  • Rxsight Inc$436
  • Bausch & Lomb Americas Inc.$411
  • Alcon$197
  • Sight Sciences, Inc.$174
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,74999%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,789 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$445,187
Medicare patients
1,187
Services billed
3,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine70$85,017
XiidraLifitegrast30$46,278
LumiganBimatoprost52$27,530
Cyclosporine24$15,024
Prednisolone Acetate167$9,938
VyzultaLatanoprostene Bunod15$9,474
Brimonidine Tartrate29$8,505
TyrvayaVarenicline Tartrate12$8,104
ProlensaBromfenac Sodium19$6,637
Loteprednol Etabonate34$5,515
Ketorolac Tromethamine195$4,796
TobradexTobramycin/Dexamethasone17$4,564
Latanoprost341$4,532
Travoprost22$3,317
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$612$112,547122 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$411$55,75245 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$144$12,15253 claims
Oyster Point Pharma, Inc.Tyrvaya$128$8,10412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Westwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →